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Over the past two decades, research has identified extrasynaptic GABAA receptor populations that enable
neurons to sense the low ambient GABA concentrations present in the extracellular space in order to
generate a form of tonic inhibition not previously considered in studies of neuronal excitability. The impor-
tance of this tonic inhibition in regulating states of consciousness is highlighted by the fact that extrasynaptic
GABAA receptors (GABAARs) are believed to be key targets for anesthetics, sleep-promoting drugs,
neurosteroids, and alcohol. The neurosteroid sensitivity of these extrasynaptic GABAARs may explain their
importance in stress-, ovarian cycle-, and pregnancy-related mood disorders. Moreover, disruptions in
network dynamics associated with schizophrenia, epilepsy, and Parkinson’s disease may well involve
alterations in the tonic GABAAR-mediated conductance. Extrasynaptic GABAARs may therefore present
a therapeutic target for treatment of these diseases, with the potential to enhance cognition and aid post-
stroke functional recovery.The GABAergic system of the mammalian brain consists of
GABA-releasing cells and receptors that bind GABA. GABA-
releasing cells are extraordinarily diverse and highly specialized
(Freund and Buzsa´ki, 1996; Klausberger and Somogyi, 2008),
both controlling the activity of local networks (e.g., interneurons)
and forming the output of some brain areas and nuclei (e.g., stria-
tal medium spiny neurons and cerebellar Purkinje cells). Recep-
tors that bind GABA are present on virtually every neuron in the
brain and represent a diverse array of receptor types (Mody
and Pearce, 2004). This review focuses on GABAA receptors
(GABAARs) that are excluded from synapses (see Figure 1). It
has long been appreciated that ligand-gated ion channels that
bind glutamate and GABA are found outside synapses in the
somatic, dendritic, and even axonal membranes of mammalian
neurons (Brown et al., 1979; Soltesz et al., 1990). The first indi-
cation that a persistent, tonic conductance could result from
activation of extrasynaptic GABAAR populations came from
whole-cell voltage-clamp recordings made from developing
neurons when synapses are being formed (Ben-Ari et al., 1994;
Kaneda et al., 1995; Valeyev et al., 1993). In these experiments,
the addition of GABAAR blockers reduced the standing holding
current indicating that a tonic GABAAR-mediated conductance
had to be present that was not associated with conventional
IPSCs (Otis et al., 1991). It is believed that these early develop-
mental forms of GABA signaling may play a role in controlling
neuronal differentiation (LoTurco et al., 1995; Markwardt et al.,
2011; Owens et al., 1999). This type of intercellular commu-
nication is fundamentally different from the ‘‘point-to-point’’
communication that underlies both synaptic transmission and
gap-junction-mediated electrical coupling. It is more similar to
the volume and paracrine transmission associated with the
actions of neuromodulators such as serotonin, histamine, dopa-
mine, acetycholine, and peptides in the brain (Agnati et al., 2010).
Attention has subsequently focused on the molecular identityof the extrasynaptic GABAARs that generate the tonic con-
ductance and on exploring their physiological relevance for
the adult brain (Farrant and Nusser, 2005).
GABAARs are pentameric assemblies usually made up from at
least three different proteins selected from 19 different subunits
(Olsen and Sieghart, 2008). These include a1-6, b1-3, g1-3, d, ε,
q,p, and r1-3 (Olsen and Sieghart, 2008, 2009; Whiting, 2003). A
receptor’s regional and developmental expression pattern, as
well as its physiological and pharmacological properties, are
determined by differences in subunit gene expression and com-
position (Hevers and Lu¨ddens, 1998; Mody and Pearce, 2004)
and the rules governing these relationships have received a
great deal of attention in the search for highly specific drug
targets in the CNS (Olsen and Sieghart, 2009; Whiting, 2003).
The subunit identity of the final assembly also determines the
synaptic or extrasynaptic localization of GABAARs within
a neuron (Pirker et al., 2000), reflecting the existence of various
subunit assembly rules and anchoring/trafficking mechanisms
(Luscher et al., 2011; Vithlani et al., 2011). Following the original
description of the GABAAR d-subunit (Shivers et al., 1989) and its
expression patterns in the brain (Wisden et al., 1992), it was first
shown for mature cerebellar granule cells that extrasynaptic
a6bd subunit-containing GABAARs mediate a tonic form of
inhibition both in vitro (Brickley et al., 2001; Hamann et al.,
2002) and in vivo (Chadderton et al., 2004), while conventional
synaptic g2 subunit-containing GABAARs are involved in direct
synaptic transmission (Farrant and Nusser, 2005). A tonic
conductance mediated by a4bd subunit-containing GABAARs
has now also been reported in dentate gyrus granule cells,
thalamic relay neurons, neocortical layer 2/3 pyramidal cells,
and medium spiny neurons of the striatum (Ade et al., 2008;
Drasbek and Jensen, 2006; Kirmse et al., 2008; Porcello et al.,
2003; Salin and Prince, 1996; Santhakumar et al., 2010;
Stell et al., 2003). Additionally, a tonic conductance present inNeuron 73, January 12, 2012 ª2012 Elsevier Inc. 23
Figure 1. Tonic Inhibition Mediated by Extrasynaptic GABAA Receptors
The dendrite/soma of a neuron receives a constant barrage of synaptic drive from glutamatergic andGABAergic terminals. The astrocytes that closely intermingle
with these structures sense the release of these neurotransmitters as well as modulating their levels within the extracellular space. Vesicular GABA release from
GABAergic terminals aswell as nonvesicular GABA release from other sources interacts with GABA uptakemechanisms to set the ambient GABA levels within the
extracellular space.
(A) Phasic inhibition. GABA molecules are packaged into synaptic vesicles within the GABAergic terminal. Once released, GABA rapidly diffuses across the
synaptic cleft to occupy synaptic GABAARs that can exist in various subunit compositions. The low affinity of synaptic receptors means that although the synaptic
cleft concentration is high (1–10 mM) the GABA molecules only occupy the receptors for a very short duration. Brief GABAAR occupancy is further ensured by
the rapid removal of GABA from the synaptic cleft (<1 ms) due to diffusion and active binding and uptake by GABA transporter proteins (GAT-1) located in
the presynaptic axon terminal. The resulting brief postsynaptic conductance change (white trace) is characterized by a fast rising and slow decaying waveform
that can vary in duration depending upon the subunit composition of the synaptic GABAARs and the transmitter profile within the cleft.
(B) Tonic inhibition. The low resting ambient GABA levels present in the extracellular space are able to activate high-affinity extrasynaptic GABAARs to generate
a persistent conductance (Cl and to a lesser extent HCO3
) that is responsible for generating tonic inhibition (noisy white trace) in a number of neuronal types.
(C) Ambient GABA levels. The precise mechanisms for regulating ambient GABA levels within the brains extracellular space is beginning to be elucidated and
involves an interplay between the level of vesicular GABA release, the stoichiometry of the GABA transporters (GAT-2 and BGT-1 in astrocytes and GAT-1 in axon
terminals), and other forms of nonvesicular GABA release such as GABA permeation through bestrophin channels. Ultimately, it is the level of ambient GABA that
leads to the activation of extrasynaptic GABAARs in the soma/dendrite and even axonal membrane to generate tonic inhibition.
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et al., 2007) is probably generated by the persistent activation
of extrasynaptic a1bd subunit-containing extrasynaptic
GABAARs (Ola´h et al., 2009).
Given that persistently active d-GABAAR openings make such
a major contribution to the total charge that flows across the
membrane (Belelli et al., 2005; Brickley et al., 1996; Nusser
and Mody, 2002), it is not surprising that this type of conduc-
tance is capable of modulating both cell and network behavior
(Farrant and Nusser, 2005). In thalamic relay neurons, for
example, the membrane hyperpolarization associated with the
persistent chloride flux through d-GABAARs leads to burst firing
(Cope et al., 2005) and slow thalamo-cortical oscillations (Win-
sky-Sommerer et al., 2007). However, the tonic conductance
may not always result in membrane hyperpolarization. In cere-
bellar granule cells, the membrane shunt associated with tonic24 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.inhibition attenuates excitatory drive with little impact on the
membrane potential (Brickley et al., 2001). It is also worth noting
that a shunting inhibition associated with a tonic conductance
could result in a small but persistent membrane depolarization
(Farrant and Kaila, 2007). Another striking feature of the tonic
conductance measured in adult neurons is that it represents
the simultaneous opening of only a very small fraction of the
available extrasynaptic GABAARs (Kasugai et al., 2010; Nusser
et al., 1995), indicating that receptor occupancy is low and/or a
large number of receptors are heavily desensitized. d-GABAARs
recorded at room (Mortensen et al., 2010) and physiological
(Bright et al., 2011) temperatures are predicted to be profoundly
desensitized. Although tonic inhibition can be generated by
a desensitized receptor population as long as receptor
number is high, this feature could limit the ability of these
receptors to operate as spillover detectors and other less
Neuron
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this role. Slow-rising and slow-decaying IPSCs generated by
GABA spillover is a significant feature of GABA release from
Ivy/neuorgliaform cells (Capogna and Pearce, 2011; Szabadics
et al., 2007) and has been reported in hippocampal neurons
(Vargas-Caballero et al., 2010; Zarnowska et al., 2009). One
challenge for the future is to establish whether the spillover
currents observed in these and other cell types reflect activation
of distinct extrasynaptic GABAAR populations separate from
those responsible for generating tonic inhibition (Farrant and
Nusser, 2005).
It is now appreciated that in addition to d-GABAARs, other
GABAAR types are also capable of generating a tonic conduc-
tance in a number of adult brain regions. Most notably, a5bg2
subunit-containing GABAARs (a5-GABAARs) generate a tonic
conductance that regulates the excitability of pyramidal neurons
in CA1 and CA3 regions of the hippocampus (Caraiscos et al.,
2004; Glykys andMody, 2006, 2007; Pavlov et al., 2009; Prenosil
et al., 2006; Semyanov et al., 2004) and layer 5 cortical neurons
(Yamada et al., 2007). High-affinity GABAARsmade up of only ab
subunits are also a possibility (Mortensen and Smart, 2006), as
are GABAARs that can open even in the absence of an agonist
(Hadley and Amin, 2007), as reported in some immature neurons
(Birnir et al., 2000). It is also possible, given the large number of
g2-GABAARs present in both the synaptic and extrasynaptic
membrane (Kasugai et al., 2010; Nusser et al., 1995; Soltesz
et al., 1990), that more conventional low-affinity GABAARs
make a contribution to the steady-state conductance when
ambient GABA concentrations are high (Farrant and Kaila,
2007). Nevertheless, it is now appreciated that specific
high-affinity GABAAR populations, such as d-GABAARs and
a5-GABAARs, are predominantly responsible for generating the
tonic conductance found in many brain regions under normal
physiological conditions. The study of these extrasynaptic
GABAAR populations is now entering a defining stage and this
review focuses on new insights into the potential involvement
of these receptors in the cellular and molecular abnormalities
underlying neurological and psychiatric disorders including
sleep disturbances, stress-related psychiatric conditions, and
epilepsy. We also further discuss the potential role of these
receptors in cognition, in recovery from stroke, and in mediating
the effects of alcohol.
Sleep Disorders
Adequate sleep is essential for our well being, and many neuro-
psychiatric conditions, such as depression and schizophrenia,
are associated with severe disruptions in sleep patterns. It is
thus disappointing that we understand little about the mecha-
nisms that control sleep and rely on limited repertoires of clinical
interventions to treat sleep disorders (Wafford and Ebert, 2008).
GABAARs play a pivotal role in the control of our sleep rhythms,
and for many decades benzodiazepines and zolpidem, known
for their ability to potentiate GABAAR currents, have remained
the most widely prescribed treatment for insomnia, in spite of
producing tolerance, addiction, and withdrawal problems. In
a search for more refined drug interventions, it has become clear
that the hypnotic actions of the sleep promoting drug gaboxadol
(Wafford and Ebert, 2006) (4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyridin-3-ol; THIP) can be attributed to this drug’s selective
action on d-GABAARs (Brown et al., 2002). At concentrations
of around 500 nM, this drug activates d-GABAARs with little
action on synaptic GABAAR types. This selectivity arises from
gaboxadol’s lower apparent affinity at g2-GABAARs compared
to d-GABAARs (Mortensen et al., 2010). Gaboxadol acts as
a hypnotic in humans to increase sleep duration by promoting
slow-wave or non-rapid eye movement (non-REM) sleep (Faul-
haber et al., 1997). When d-GABAARs are removed by genetic
manipulations in mice, gaboxadol-induced slow oscillations
are absent from the EEG (Winsky-Sommerer et al., 2007) and
the anesthetic potency of gaboxadol is reduced (Boehm et al.,
2006). Unfortunately, due to side-effects such as hallucinations
and disorientation in a subset of patients, gaboxadol failed
phase III clinical trials as an alternative to benzodiazepines, but
more potent d-GABAAR selective agonists are being developed
(Wafford et al., 2009).
Alterations in the dynamics of the thalamo-striatal-cortical
network probably underlie the sleep disturbances common to
many neurological disorders and this may involve alterations in
extrasynaptic GABAAR function. In the thalamus a tonic GABA
conductance promotes burst firing of thalamic relay neurons
(Bright et al., 2007; Cope et al., 2005), a key requirement in the
generation of slow 1–4 Hz EEG rhythms during non-REM sleep.
During non-REM sleep, ambient GABA levels are higher in the
thalamus than during REM or waking states (Ke´kesi et al.,
1997). d-GABAARs are also found in the superficial neocortical
layers 2/3 but there is currently little evidence to suggest that
these neocortical d-GABAARs contribute to the slow thalamo-
cortical rhythms observed during sleep (Steriade et al., 1993).
In Parkinson’s disease, sleep abnormalities are among the
frequent nonmotor symptoms that present during its early evolu-
tion prior to drug treatment (Chaudhuri and Naidu, 2008). The
caudate-putamen of the striatum is a brain region that regulates
motor planning and is, therefore, critically linked to Parkinson’s
disease. This brain region also expresses high levels of extrasy-
naptic a4bd subunit-containing GABAARs and dopamine D1
receptor-expressing medium spiny neurons display a tonic
conductance-mediated by d-GABAAR populations (Ade et al.,
2008; Kirmse et al., 2008). The loss of dopaminergic drive that
characterizes Parkinson’s disease explains the enhanced
GABA concentrations found in the striatum (Kish et al., 1986)
and it is intriguing to speculate that this change may underlie
the sleep disruptions associated with Parkinson’s and alter-
ations in ambient GABA levelsmay contribute to the sleep distur-
bances commonly associated with a number of neurological
disorders including depression.
Drugs that modulate sleep and induce anesthesia share
common molecular targets (Franks, 2008). Raising ambient
GABA levels alone, with GABA uptake blockers, will induce an
anesthesia-like state (Katayama et al., 2007) and neurosteroids
(which are brain-synthesized metabolites of ovarian and adrenal
cortical steroid hormones) act as anesthetics through an action
on d-GABAARs (Stell et al., 2003). Indeed, the loss of d-GABAARs
is associated with an attenuated response to neurosteroid-
induced anesthesia (Mihalek et al., 1999). Other important
general anesthetics such as propofol and isoflurane enhance
tonic inhibition in hippocampal neurons (Bai et al., 2001),Neuron 73, January 12, 2012 ª2012 Elsevier Inc. 25
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neurons (Drasbek et al., 2007). However, the amnesia-inducing
effect, but not the anesthetic potency of isoflurane, is altered
in a4 knockout mice, which also lack d-GABAARs on the cell
surface (Rau et al., 2009), demonstrating that extrasynaptic
GABAARs are not a primary site of action for all anesthetics.
Stress and Psychiatric Disorders
Neurosteroids are among the most powerful regulators of
GABAAR function in the CNS (Belelli and Lambert, 2005; Chisari
et al., 2010; Mitchell et al., 2008; Reddy, 2010). The first
example of this robust modulatory effect was discovered nearly
30 years ago (Harrison and Simmonds, 1984) for the synthetic
steroid alphaxalone (5a-pregnan- 3a-ol-11,20 dione). Shortly
after, it was demonstrated that a metabolite of the ovarian
steroid hormone progesterone (allopregnanolone, also called
3a-hydroxy-5a-pregnan-20-one, or 3a,5a-tetrahydroprogester-
one, or 5a-pregnan-3a-ol-20-one, or 5a3a-THPROG) and a
metabolite of the stress steroid deoxycorticosterone (aka
5a3a-THDOC) are potent barbiturate-like ligands of GABAARs
(Majewska et al., 1986). Our first collaborative research (Stell
et al., 2003) demonstrated that d-GABAARs are a preferred
site of action for neurosteroids at low (nanomolar) concentra-
tions. This preferred action probably reflects a simple property
of these receptors: GABA is not an efficacious agonist at
d-GABAARs (Chisari et al., 2010), which means that the
coupling of GABA binding to channel opening is not efficient.
Because neurosteroids increase the likelihood that GABA will
open the channel (Chisari et al., 2010), they can enhance the
efficacy of GABA at d-GABAARs and thus modulate receptor
activity, while this is less likely at other GABAARs where
GABA is already an efficacious agonist. Perhaps d-GABAARs
are the preferred site of action for paracrine neurosteroid
signaling where the neurosteroids synthesized in another cell
(e.g., astrocyte) must travel through the extracellular space to
act on extrasynaptic d-GABAARs. Neurosteroid synthesis in
astrocytes is regulated by the mitochondrial 18 kD translocator
protein TSPO (the peripheral benzodiazepine receptor by its
former name) for which the drug XBD173 is an excellent nonse-
dative anxiolytic and antipanic agent (Rupprecht et al., 2009).
The mitochondrial TSPO is also in CNS neurons where it may
mediate autologous effects of neurosteroids on neuronal excit-
ability in brain slices following benzodiazepine (Tokuda et al.,
2010) or ethanol (Tokuda et al., 2011) administration.
Since neurosteroid levels in the brain will also mirror ovarian
or stress steroid hormone levels, the tonic inhibition regulated
by the neurosteroid metabolites of these hormones may con-
tribute to CNS disorders associated with altered hormonal
states. For example, the anxiety associated with premenstrual
dysphoric disorder (PMDD) has been linked to neurosteroid
regulation of tonic inhibition in animals (Maguire et al., 2005;
Smith et al., 1998) and the discrepancy between extrasynaptic
GABAAR number and postpartum levels of the progesterone
metabolite allopregnanolone has been linked to postpartum
depression (Maguire and Mody, 2008). During pregnancy,
progesterone levels increase by over 100-fold, and the levels
of allopregnanolone (produced in the brain from progesterone),
which could potentially enhance inhibition through d-GABAARs,26 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.are elevated accordingly. High neurosteroid levels in the brain
are dangerous because they might produce an anesthetic-like
effect by sedating expectant mothers. Most likely as a com-
pensatory mechanism, the number of neurosteroid-sensitive
d-GABAARs decrease during pregnancy, so that the high levels
of neurosteroids are offset by fewer d-GABAARs. However, this
balance in the mother’s brain recalibrates just after delivery,
when progesterone and neurosteroid levels are restored. With
the postpartum drop in neurosteroid levels, the reduced
numbers of d-GABAARs are no longer sufficient to maintain an
optimal level of inhibitory tone. The result is a period of increased
neuronal excitability until the number of d-GABAARs is restored
to prepregnancy levels. In our experiments, we found that delays
in d-GABAAR recovery were associated with severe depression-
like behavior in mice, which results in mothers cannibalizing their
offspring. This behavior is reduced by administering gaboxadol
to activate the d-GABAARs. The recently identified selective
d-GABAAR agonist (DS-1) and an allosteric enhancer (DS-2) of
d-GABAAR function (Wafford et al., 2009) may aid the design
of specific treatments for postpartum depression. Analogous
changes in d-GABAAR expression have also been reported to
occur during puberty (Shen et al., 2007), which could in part
explain why this developmental period is associated with
increased susceptibility to stress-related disorders.
Stress induced by social isolation in rats leads to upregulation
of extrasynaptic d-GABAARs and correlates with an increase in
hippocampal tonic inhibition (Serra et al., 2006). Hippocampal
tonic inhibition counteracts the excitation of interneurons and
can regulate the frequency of gamma oscillations (Mann and
Mody, 2010) that have been shown to be altered in schizo-
phrenic patients (Uhlhaas and Singer, 2010). The observation
that reductions in d-GABAAR mRNA have been reported in
post-mortem brains of patients with schizophrenia (Maldo-
nado-Avile´s et al., 2009), and the association between two poly-
morphisms in the GABRD gene and childhood onset mood
disorders in males (Feng et al., 2010), potentially suggests that
altered tonic conductance could explain the disturbances in
network behavior described in such disorders. Interestingly, in
humans the GABAAR a5 subunit gene has also been identified
as a susceptibility locus for schizophrenia (Maldonado-Avile´s
et al., 2009) and depression (Kato, 2007). Autopsy studies
from individuals who have suffered from major depression
exhibit marked changes in a number of genes involved in both
glutamate and GABA signaling pathways, including alterations
in the expression of a5-GABAARs and d-GABAARs (Choudary
et al., 2005; Sequeira et al., 2009). Although many genes,
including those involved in synaptic GABAAR function, can be
altered in neuropsychiatric disorders an emerging theme of
these and many other studies is that the a5 and d containing
GABAARs are heavily regulated by stress hormones, and
this feature is likely to explain why changes in extrasynaptic
GABAA receptor expression are so often associated with
stress-related disorders.
Epilepsy
Disturbances in synaptic and extrasynaptic GABAAR function,
including several point mutations (Macdonald et al., 2010),
have been implicated in many forms of epilepsy. Given the
Table 1. Summary of Some Clinically Relevant Drugs that Can Alter Tonic Inhibition within the Brain
Drug (Trade Names) Mechanism of Action Current Drug Indications
Gabapentin (Fanatrex,
Gabarone, Gralise, Neurontin)
Originally thought to be a GABA mimetic,
but mechanism of action is now unclear.
Possible enhancement of GABA synthesis
could explain why ambient GABA levels in
the brain are raised (Maneuf et al., 2003).
Partial-onset seizures in adults and the
elderly (Beghi, 2010); alcohol withdrawal as
a combination therapy (Anton et al., 2011);
sleep disorders (Ehrenberg, 2000).
Vigabatrin
(Sabril)
Irreversible block of GABA transaminase to
interfere with GABA cetabolism and,
therefore, raise ambient GABA levels.
Refractory complex partial seizures and
infantile spasms (Tolman and Faulkner,
2009). Not favored due to visual field loss
in some adults and children (Chiron and
Dulac, 2011).
Tiagabine (Gabitril) Blockade of GABA transporters on nerve
terminals (predominantly GAT-1) leads to
raised ambient GABA levels.
Partial seizures; generalized anxiety
disorders/panic disorders
(Pollack et al., 2005).
Pregabalin (Lyrica) Enhances the activity of glutamic acid
decarboxylase (GAD) leading to increased
GABA synthesis and, therefore, raised
ambient GABA levels.
Partial seizures with or without secondary
generalization (Tassone et al., 2007);
neuropathic pain in diabetese, postherpetic
neuralgia, and fibromyalgia (Tassone et al.,
2007); generalized anxiety disorder
(Tassone et al., 2007).
Gaboxadol Selective orthosteric agonist at d-GABAARs
leading to specific enhancement of the
tonic conductance.
Sleep enhancer, but withdrawn from
Phase III clinical trials due to poor
risk-to-benefit ratio (Saul, 2007).
L-655,708 High-affinity negative allosteric modulator
of a5-GABAARs that will reduce tonic
conductances.
Cognitive enhancer but not thought to be
suitable for human use due to anxiogenic
properties (Navarro et al., 2002).
Ganaxolone Positive allosteric modulator of most
GABAARs with greater potency at
d-GABAARs leading to selective
enhancement of the tonic conductance.
Catemenial epilepsy (Biagini et al., 2010).
Alphaxalone (Althesin, Saffan) Positive allosteric modulator of most
GABAARs with greater potency at
d-GABAARs leading to selective
enhancement of the tonic conductance.
Anesthetic (Winter et al., 2003) and sedative
in long-term intensive care patients
(Stewart et al., 1983). Was withdrawn from
clinical practice due to complications with
the vehicle, Cremophor EL.
Rebranded as Saffan and widely used as an
anesthetic in veterinary surgery.
Propofol (Diprivan) Positive allosteric modulator of most
GABAARs including a5 and d-GABAARs
leading to enhanced tonic conductance.
Widely used as an intravenous anesthetic.
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for the control of neuronal network behavior (Vida et al., 2006),
it is not surprising that d-GABAARs are targets in the treatment
of specific forms of epilepsy. Several of the drugs listed in Table
1, which are already in clinical use as antiepileptics, modulate
tonic inhibition by altering ambient GABA levels in the brain
(see also Figure 2). Mutations in the d subunit gene have also
shown some degree of association with genetic forms of human
epilepsy (Dibbens et al., 2004; Mulley et al., 2005) and mouse
models of temporal lobe epilepsy (Peng et al., 2004) involve
changes in tonic inhibition within the hippocampus (Maguire
et al., 2005; Peng et al., 2004; Spigelman et al., 2002; Zhang
et al., 2007). The neurosteroid analog ganaxolone is in clinical
trials for the treatment of catamenial epilepsy, a form of epilepsy
in women that shows cyclic variations in the frequency and
intensity of seizures depending on the phases of the menstrualcycle. d-GABAAR-mediated tonic inhibition has been shown to
change during the ovarian cycle (Maguire et al., 2005). As extra-
synaptic d-GABAARs are highly sensitive to modulation by neu-
rosteroids such as progesterone (Stell et al., 2003), the ability
of ganaxolone to enhance tonic inhibition (Belelli and Herd,
2003) could explain why this drug protects against seizure during
these sensitive periods of the ovarian cycle. However, enhancing
tonic inhibition is not a useful strategy for the treatment of all
epilepsies. For example, slow wave discharges within the
thalamo-cortical network are a defining feature of absence
seizures. Paradoxically, this type of seizure is triggered by
enhanced d-GABAAR openings with the GABA agonist gaboxa-
dol (Fariello and Golden, 1987). In rodents, a model of absence
epilepsy correlates with increased levels of tonic inhibition on
thalamic relay neurons (Cope et al., 2009) due to dysfunction
of the GABA transporter (GAT-1) and the resulting elevatedNeuron 73, January 12, 2012 ª2012 Elsevier Inc. 27
Figure 2. Pharmacological Strategies for
Altering the Tonic Conductance
A number of clinically relevant drugs are available
that are known to alter the tonic conductance via
a variety of direct and indirect targets. Here we
illustrate a number of these targets situated within
the principal neuronal and nonneuronal compart-
ments of the brain. Although it was originally
thought to be a GABA mimetic, the mechanism of
action for Gabapentin is currently unclear, but the
drugs ability to increase ambient GABA levels in
the brain could reflect an alteration in GABA
synthesis or release. Gabapentin is currently
prescribed for the treatment of partial-onset
seizures in adults and the elderly as well as a
combination therapy for alcohol withdrawal and
for sleep disorders. Tiagabine is a GABA trans-
porter blocker acting predominantly on GAT-1 in
nerve terminals leading to raised ambient GABA
levels. This drug is prescribed for the treatment of
partial seizures as well as generalized anxiety
disorders/panic disorders. Other GABA trans-
porter blockers such as SNAP-5114 are more
selective blockers of GABA uptake in astrocytes, but these also lead to enhanced ambient GABA levels. Although bestrophin-1 channels could be an alternative
nonvesicular source of GABA release, blockade of these channels by NPPB [5-nitro-2-(3-phenylpropylamino) benzoic acid] has been reported to both increase
(Rossi et al., 2003) and decrease tonic inhibition (Lee et al., 2010) onto cerebellar granule cells. Irreversible block of GABA transaminase with the prescription
drug Vigabatrin represents another strategy for raising ambient GABA levels. Vigabatrin has been used for the treatment of refractory complex partial seizures
and infantile spasms but is currently not favored due to visual field loss in some adults and children. More direct mechanisms for altering tonic inhibition involve
orthosteric and allosteric interactions with extrasynaptic GABAARs. For example, the orthosteric agonist THIP or gaboxadol will selectively activate d-GABAARs
and, therefore, promote non-REM sleep. DS-1 is a newly developed agonist that has greater selectivity for d-GABAARs than THIP, but its clinical benefit has yet to
be established. Inverse agonists such as L-655,508 are currently being used to block the current generated by a5-GABAARs with the general objective to being
used as cognitive enhancers. Allosteric modulators such as neurosteroids also offer a mechanism for more directly enhancing tonic inhibition. One such drug,
Ganaxolone, is currently being developed for the treatment of drug resistant forms of catamenial epilepsy. It may also be possible to enhance or reduce tonic
inhibition with Finasteride that blocks neurosteroid synthesis and XBD173 that enhances neurosteroid synthesis via the mitochondrial 18 kD translocator protein
TSPO. It is also possible that the b subunit isoform identity may provide a means for selectively modulating tonic inhibition as the preferred b partner is the b2
subunit (Belelli and Lambert, 2005; Belelli et al., 2005; Herd et al., 2008) for a4bd subunit-containing GABARs in the thalamus and dentate gyrus of the hippo-
campus. Any future development of b-subunit-dependent phosphorylation drugs could be useful in this regard.
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The membrane hyperpolarisation that occurs following en-
hanced tonic conductance in thalamic relay neurons (Cope
et al., 2005) alters the fine balance of the thalamo-cortical
network (Bright et al., 2007), leading to slow wave discharges.
These observations provide a plausible explanation why treat-
ment of absence seizures in humans, with drugs like tiagabine
and vigabatrin, exacerbates this particular form of epilepsy
(Perucca et al., 1998).
Effects of Alcohol on the Brain
Unlike other addictive drugs that have well-defined targets in
the CNS (e.g., cannabis and cocaine), the intoxicating actions
of alcohol have poorly defined molecular targets (Kumar et al.,
2009). To demonstrate measurable and consistent effects on
neuronal targets, past in vitro studies have used higher ethanol
concentrations than those considered to be performance impar-
ing. In the U.S., for example, every state sets the legal threshold
for blood alcohol concentration at 0.08%, which corresponds
to 17 mM ethanol in the blood. Thus, intoxicating alcohol
concentrations within a physiologically relevant range should
be used when searching for brain targets of ethanol. In expres-
sion systems, d-GABAARs containing the a4, a6, a1, and b2 or
b3 subunits are all potentiated by ethanol at intoxicating con-
centrations (Sundstrom-Poromaa et al., 2002). Moreover,
ethanol’s action on d-GABAARs was demonstrated in native
neurons (Fleming et al., 2007; Hanchar et al., 2005; Jia et al.,
2008a; Liang et al., 2007; Santhakumar et al., 2007; Wei et al.,28 Neuron 73, January 12, 2012 ª2012 Elsevier Inc.2004). However, a number of studies have failed to replicate
these findings in heterologous expression systems (Baur et al.,
2009; Borghese et al., 2006; Korpi et al., 2007; Yamashita
et al., 2006), calling into question extrasynaptic d-GABAARs as
a molecular target for intoxicating ethanol concentrations.
Indeed, antagonism of the putative alcohol binding site on the
d-GABAAR does not alter alcohol-related behavioral responses
in vivo (Linden et al., 2011). It is of course possible that acute
effects are due to indirect actions of alcohol on d-GABAARs
(Kumar et al., 2009), either by enhancing vesicular GABA release
(Carta et al., 2004) or by enhancing neurosteroid synthesis
(Sanna et al., 2004). Hopefully, it will not be too long before
a consensus is reached on the acute actions of intoxicating
levels of alcohol in the brain.
In the context of the underlying pathophysiology in alcohol
dependence, d-GABAARs may contribute to the effects of
alcohol on the reward system of the brain responsible for rein-
forcing continued alcohol abuse. RNA interference (RNAi) to
reduce the expression of a4 subunits (Rewal et al., 2009) or of
d subunits (Nie et al., 2011) in the nucleus accumbens dorsome-
dial shell decreased ethanol intake and alcohol preference in
rats. Since this highly circumscribed region of the nucleus ac-
cumbens is the preferred site of self-administration for alcohol
and other drugs of abuse such as amphetamine, cocaine, or
dopamine receptor agonists, novel mechanisms of acute and
chronic ethanol actions on d-GABAARs discovered over the
past decade are beginning to form a cohesive picture, and con-
stitute a first step in understanding the role of the GABAergic
Neuron
Reviewsystem in alcohol abuse, tolerance, and dependence. Addition-
ally, long-term alcohol abuse alters GABAAR expression
patterns in both animal models and postmortem brain tissue
(Kumar et al., 2009). Understanding how changes in extrasynap-
tic GABAAR function may impact upon addictive behavior could
lead to more rational strategies for the treatment of alcohol
dependence and abuse.
Learning and Memory/Cognition Enhancement
After the discovery of long-term potentiation (LTP) (Bliss and
Lomo, 1970) at glutamatergic synapses, a form of neuronal plas-
ticity widely thought to underlie learning and memory, it was
discovered that GABAergic inhibition obstructs this plasticity
(Wigstro¨m and Gustafsson, 1983). Low doses of picrotoxin,
a noncompetitive antagonist that blocks synaptic and extrasy-
naptic GABAARs, alleviates learning and memory deficits in
mouse models of Alzheimer’s disease (Yoshiike et al., 2008),
neurofibromatosis (Cui et al., 2008), and Down syndrome (Fer-
nandez et al., 2007). Specific blockers of tonic inhibition medi-
ated by a5-GABAARs and knockout mice for the a5-GABAARs
have also provided insights into how these receptors, and the
tonic inhibition they mediate, impede learning and cognition
(Atack, 2010; Martin et al., 2009). First, mice with a partial or
full deficit of a5-GABAARs show improved performance in
associative learning and memory tasks (Collinson et al., 2002;
Crestani et al., 2002; Yee et al., 2004), with only a minimal deficit
in memory for object location (Prut et al., 2010). Second, nega-
tive allosteric modulators (or BZD-site inverse agonists) selective
for a5-GABAARs, such as a5IA, L-655,708, or RO-493851, all
enhance learning and cognitive performance in rodents (Ballard
et al., 2009; Chambers et al., 2004; Dawson et al., 2006; Navarro
et al., 2002) while having no proconvulsant effects. Data in
humans are scarce, but an ethanol-induced amnesia was
reduced by administering a5IA to healthy volunteers (Nutt
et al., 2007). In hippocampal pyramidal cells, the elevated
numbers of d-GABAARs and enhanced allopregnanolone levels
during puberty reduce the probability of inducing LTP (Shen
et al., 2010). Adolescent mice also exhibited deficits in an LTP-
dependent spatial learning task, which are reversed in adoles-
cent mice lacking d-GABAARs. The continuing development
and refinement of negative allosteric modulators specific for
a5-GABAARs (Knust et al., 2009), and other drugs that modulate
tonic inhibition mediated by d-GABAARs, hold promise as novel
treatments for Alzheimer’s disease or other neurological and
psychiatric disorders characterized by deficits in learning,
memory, or cognition.
Neuroprotection and Recovery of Function after Stroke
or Other Brain Injuries
It has been suggested that recovery of function following acute
injury to the sensorimotor cortex may be controlled by the
availability of GABA (Levy et al., 2002). Enhanced tonic inhibition
has an acute neuroprotective quality. For example, medium
spiny neurons (MSNs) of the striatum are protected against
quinolinic acid or NMDA receptor-mediated toxicity by tonic
inhibition (Santhakumar et al., 2010). Compared to wild-type,
MSNs from adult mice lacking d-GABAARs had both decreased
tonic GABA currents and reduced MSN survival following anin vitro excitotoxic challenge with quinolinic acid. Furthermore,
following acute exposure of MSNs to NMDA in WT, but not
mice lacking d-GABAARs, muscimol-induced tonic GABA
currents reduced the acute swelling of the neurons. In a cortical
stroke model, the increased size of the cortical lesion observed
when the tonic conductance was reduced with an inverse
agonist immediately after an experimental photothrombotic
stroke also indicates an acute neuroprotective role for tonic
inhibition in cortical neurons (Clarkson et al., 2010). These find-
ings suggest targeting of extrasynaptic GABAARs that mediate
tonic inhibition could potentially be developed as novel strate-
gies to aid post stroke recovery. The adult brain possesses
a remarkable structural and functional plasticity, but some
barriers may impede its plasticity once a developmental window
is closed (Bavelier et al., 2010). The plasticity of the brain that
occurs after an injury is particularly important as it may either
facilitate or hinder recovery of function. Plasticity can occur
after stroke, particularly in the peri-infarct zone that is adjacent
to the region devastated by the stroke (Murphy and Corbett,
2009). As our recent findings (Clarkson et al., 2010) indicate,
mechanisms involving an enhanced tonic inhibition that impede
the functional plasticity of the adult brain in learning andmemory,
such as those found in mice lacking a5-GABAARs or animals
treated with a negative allosteric modulator of a5-GABAAR,
might also be operational during post stroke recovery. Therefore,
a5-GABAAR BZD-site inverse agonists developed for treating
cognitive disorders may equally be useful as the first clinical
treatment to enhance functional recovery after stroke or possibly
other devastating brain injuries.
Conclusions
Our motivation for this review was to highlight an emerging link
between changes in tonic inhibition and pathological brain
states. There has been considerable progress in understanding
the functional significance of extrasynaptic GABAARs in the adult
brain and how the tonic conductance they generate can alter
network behavior in a number of ways. Manipulating ambient
GABA levels and/or altering extrasynaptic GABAAR function
may offer novel strategies for the treatment of a diverse array
of neurological and psychiatric disorders. The development of
drugs to alter the function of extrasynaptic GABAARs has seen
remarkable progress (see Figure 2). A number of drugs designed
to modulate a5-GABAARs may turn out to be useful as cognition
enhancers as well as removing some of the ‘‘brakes’’ in the path
of adult plasticity necessary for functional recovery after
neuronal injury. Several classes of drugs are also becoming
available to enhance the function of d-GABAARs, but the
discovery of compounds that are able to specifically antagonize
tonic inhibition mediated by d-GABAARs is still needed. The
diversity of the GABAergic system in general, and of GABAARs
in particular (Mody and Pearce, 2004), will ensure that further
advances in GABA pharmacology will provide a more targeted
treatment of these diseases.
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